ClinicalTrials.gg
RecruitingNCT07140016Updated Oct 23, 2026

A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

A Phase 1 interventional study of gilteritinib in Non-small Cell Lung Cancer (NSCLC) and Anaplastic Lymphoma Kinase (ALK) Positive, sponsored by Astellas Pharma Global Development, Inc.. Recruiting at 17 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.
Updated Oct 23, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Carcinoma, Non-Small-Cell Lung by Astellas Pharma Inc — 5 open to participants now, 7 under way, 1 of them phase 3. Carcinoma, Non-Small-Cell Lung · Astellas Pharma Inc.

Planned enrollment
23rd of 29
40 · median 103
Started
2025
with 1 other
Phase 1
10 of 29
2 open now
Registered
26th of 29
by date

Among the 29 studies in Carcinoma, Non-Small-Cell Lung by Astellas Pharma Inc, this one is the 23rd largest by planned enrollment, is one of 2 that started in 2025, is one of 10 in phase 1, and was the 26th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

5 of the 29 studies in Carcinoma, Non-Small-Cell Lung by Astellas Pharma Inc are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Carcinoma, Non-Small-Cell Lung by Astellas Pharma Inc, or all of them as a file.
02

Study summary

Genes give your body instructions on how to make proteins. Proteins are needed to keep the body working properly. Many types of cancer are caused by changes in certain genes, making them faulty. Some people with non small cell lung cancer (NSCLC) have a faulty ALK gene. ALK stands for anaplastic lymphoma kinase. People with NSCLC who have the faulty ALK gene are called ALK-positive. ALK inhibitors are an approved treatment for people with ALK positive NSCLC. Some people stop responding to treatment with ALK inhibitors over time due to more changes happening in their faulty ALK gene, so there is an unmet medical need. Gilteritinib is an approved treatment for people with acute myeloid leukemia (AML) with the faulty FLT3 gene who haven't responded to previous treatment, or their cancer came back after previous treatment. Gilteritinib also blocks changes in the ALK gene which could help people with ALK-positive NSCLC. A study needs to be done with gilteritinib in people with ALK-positive NSCLC.

The main aim of the study is to check the safety of gilteritinib in people with ALK-positive NSCLC and if they tolerate gilteritinib.

People in this study will be adults with locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC). Locally advanced means the cancer has spread to nearby tissue. Metastatic means the cancer has spread to other parts of the body. They have stopped responding to treatment with ALK inhibitors, including alectinib or lorlatinib, over time. The key reasons people cannot take part are if they have symptomatic cancers in the brain or nervous system, their cancer has spread to the thin tissue that covers the brain and spinal cord (leptomengingeal metastasis), have recently had or planning to have major surgery, have certain heart conditions, or have recently had an infection, a stroke or mini-stroke.

People in the study will take tablets of gilteritinib once a day in a 28-day cycle. They may be given up to 2 different doses of gilteritinib. People in the study will start on the lower dose but can eventually switch to the higher dose if they tolerate the lower dose and meet the safety checks.

Whilst taking gilteritinib, people will have regular scans of their tumors. People will continue taking gilteritinib until their cancer gets worse, they have medical problems from gilteritinib that they can't tolerate, they ask to stop taking gilteritinib, they start other cancer treatment or, sadly pass away. People will visit the clinic about 7 days and then 30 days after they stop taking gilteritinib. They will be asked about any medical problems and will have a safety check. After this, people who stopped taking gilteritinib, but their cancer hadn't become worse, will continue to have regular scans of their tumors. If their cancer does get worse, they will no longer have scans of their tumors. After finishing gilteritinib, people will be phoned every 12 weeks to check on their health. People will be in the study for up to 4 years, depending on how they respond to gilteritinib.

03

Conditions studied

  • Non-small Cell Lung Cancer (NSCLC)
  • Anaplastic Lymphoma Kinase (ALK) Positive

Keywords

  • Non-small cell lung cancer (NSCLC)
  • Anaplastic Lymphoma Kinase (ALK) Positive
  • gilteritinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has or cytologically confirmed locally advanced or non-small cell lung cancer (NSCLC) with a documented anaplastic lymphoma kinase (ALK) rearrangement and is not amenable to curative intent treatment.
  • Participant is willing to submit, prior to enrollment, a fresh tumor tissue sample that was collected after completion of the most recent anti-cancer treatment and before the first dose of study intervention. If it is not medically feasible for a participant to provide a fresh tumor tissue sample, enrollment into the study should be confirmed with the Astellas medical monitor. In this case, an sample must be provided.
  • Participant must have at least one prior line of ALK inhibitor-based therapy and meet one of the following criteria:

    • Participant received alectinib as the only prior ALK inhibitor regimen. Participant is ineligible or unable to tolerate approved and available therapy or is determined to potentially benefit from gilteritinib in this setting. Participant is eligible if chemotherapy was received in the or adjuvant setting, and relapse or disease progressed after 12 months from completion of the treatment.
    • Participant received lorlatinib as one of the prior ALK inhibitor regimens.
  • Participant has according to (RECIST) version 1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
  • Participant has an (ECOG) performance status of ≤ 2.
  • Participant must have had progression or recurrence of NSCLC during or following receipt of the most recent therapy.
  • Female participant is not pregnant and at least 1 of the following conditions apply:

    • Not a woman of (WOCBP).
    • WOCBP who has a negative urine or serum pregnancy test within 7 days prior to the first dose of study intervention and agrees to follow the guidance from the time of through at least 180 days after final study intervention administration.
  • Female participant must not be breastfeeding or lactating starting at screening and throughout the period and for 60 days after final study intervention administration.
  • Female participant must not donate ova starting at the first administration of study intervention and throughout the investigational period and for 180 days after final study intervention administration.
  • Male participant must agree to use contraception with female partner(s) of childbearing potential (including breastfeeding partner) throughout the treatment period and for 120 days after final study intervention administration.
  • Male participant must agree to remain abstinent or use a condom with pregnant partner(s) for the duration of the pregnancy throughout the investigational period and for 120 days after final study intervention administration.
  • Male participant must not donate sperm during the treatment period and for 120 days after final study intervention administration.
  • Participant must meet the criteria as indicated on the clinical laboratory tests.
  • Participant agrees not to participate in another interventional study while receiving study intervention in the present study/participating in the present study.

Exclusion criteria

Exclusion Criteria:

  • Participant has known oncogenic driver alterations other than ALK rearrangement.
  • Participant has symptomatic central nervous system (CNS) or .
  • Participant has a history of other than NSCLC within 2 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix or malignancy considered cured with minimal risk of recurrence).
  • Participant had major surgery (e.g., requiring general anesthesia) within 4 weeks prior to first dose of study intervention, or will not have fully recovered from surgery, or has surgery planned during the study treatment.
  • Participant has ongoing toxicity (Grade 2 or higher with the exception of alopecia) associated with prior anti-cancer treatment.
  • Participant has/had febrile illness or symptomatic, viral, bacterial (including upper respiratory infection) or fungal (noncutaneous) infection within 28 days prior to first dose of study intervention.
  • Participant has a history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmias or torsades de pointes, structural heart disease or a family history of long syndrome.
  • Participant has a history of a cerebral vascular event (stroke or ), unstable angina, myocardial infarction or cardiac symptoms (including congestive heart failure) consistent with Class III-IV within 6 months prior to the first dose of study intervention.
  • Participant has a history of interstitial pneumonia.
  • Participant had completed target therapy, radiotherapy, chemotherapy, biologics and/or immunotherapy within 14 days prior to first dose of study intervention.
  • Participant requires treatment with strong inducers of cytochrome P450 (CYP) 3A.
  • Participant requires treatment with concomitant drugs that target serotonin 5HT1 or 5HT2B receptors or sigma nonspecific receptor with the exception of drugs that are considered absolutely essential for the care of the participant.
  • Participant has received any therapy within 14 days or 5 half-lives, whichever is longer, prior to screening.
  • Participant has a mean Fridericia-corrected QT interval (QTcF) of > 450 msec at screening.
  • Participant has known active virus (HBV) infection (defined as hepatitis B surface antigen (HBsAg)-positive and/or anti-HBV core antibody-positive) or known active virus (HCV) infection (defined as HCV RNA [qualitative] detected).

    • Participant with HBsAg-positivity and/or anti-HBV core antibody-positivity but with a negative HBV DNA PCR assay is permitted with appropriate antiviral prophylaxis or routine monitoring according to local practice.
    • Participant who has been curatively treated for HCV infection is permitted if he/she has documented sustained virologic response of 12 weeks.
  • Participant has a known history of (HIV) infection with acquired immunodeficiency syndrome (AIDS)-related complications.
  • Participant has echocardiogram (ECHO) or multigated acquisition scan () at screening revealing left ventricular ejection fraction \< 45%.
  • Participant has any condition that makes the participant unsuitable for study participation.
  • Participant has a known or suspected to gilteritinib or any components of the formulation used.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    gilteritinib

    Participants will receive gilteritinib once daily in a 28-day cycle. For participants who are tolerant and achieve stable disease after 2 scans, a dose increase will be allowed.

    Drug: gilteritinib

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants with Dose Limiting Toxicity (DLT)

    A Dose Limiting Toxicity is defined as any event meeting the DLT criteria occurring within 28 days of first dose.

    Time frame: Up to 28 Days

  2. Number of participants with Adverse Events (AEs)

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 53 Months

  3. Number of participants with Serious Adverse Events (SAEs)

    An SAE is any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires hospitalization or prolongation to hospitalization, results in persistent or significant disability/incapacity, results in congenital anomaly or birth defect, or other medically important event.

    Time frame: Up to approximately 53 Months

  4. Number of participants with laboratory value abnormalities and/or adverse events (AEs)

    Number of participants with potentially clinically significant laboratory values.

    Time frame: Up to approximately 53 Months

  5. Number of participants with vital sign abnormalities and/or adverse events (AEs)

    Number of participants with potentially clinically significant vital sign values.

    Time frame: Up to approximately 53 Months

  6. Number of participants with electrocardiogram (ECG) abnormalities and/or Adverse Events (AEs)

    Number of participants with potentially clinically significant ECG values.

    Time frame: Up to approximately 53 Months

  7. Number of participants with physical exam abnormalities and/or adverse events (AEs)

    Number of participants with potentially clinically significant physical exam values.

    Time frame: Up to approximately 53 Months

  8. Number of participants at each grade of Eastern Cooperative Oncology Group (ECOG) performance status score

    The ECOG scale will be used to assess performance status. Grades range from 0 (fully active) to 5 (dead). Negative change scores indicate an improvement. Positive scores indicate a decline in performance.

    Time frame: Up to approximately 53 Months

Secondary outcomes

  1. Objective Response Rate (ORR)

    ORR is defined as the proportion of participants whose best overall response is rated as confirmed Confirmed Response (CR) or Partial Response (PR) as assessed by investigator per Response Evaluation Criteria in Solid Tumors (RECIST) V1.1.

    Time frame: Up to approximately 53 Months

  2. Duration of Response (DOR)

    DOR is defined as the time from the date of first documented response (CR or PR that is subsequently confirmed) to the date of first documented PD as assessed by investigator based on RECIST v 1.1. or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 53 Months

  3. Disease Control Rate (DCR)

    DCR is defined as the proportion of participants whose best overall response is rated as confirmed CR, PR or stable disease as assessed by investigator based on RECIST v1.1.

    Time frame: Up to approximately 53 Months

  4. Progression Free Survival (PFS)

    PFS is defined as the time from the date of first dose of study intervention until the date of first documented progressive disease (PD) as assessed by investigator based on RECIST v 1.1. or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 53 Months

  5. Intracranial Objective Response Rate (IC-ORR)

    IC-ORR is defined proportion of participants with intracranial lesions whose best overall response rate is rated as confirmed CR or PR as assessed by investigator based on RECIST v 1.1.

    Time frame: Up to approximately 53 Months

  6. Overall Survival (OS)

    OS is defined as the time from the date of first dose of study intervention until the date of death from any cause.

    Time frame: Up to approximately 53 Months

  7. Pharmacokinetics (PK) of gilteritinib in plasma: Concentration prior to dosing at multiple timepoints (Ctrough)

    Ctrough will be derived from the PK plasma samples collected.

    Time frame: Up to approximately 6 Months

07

Study locations

16 of 17 sites recruiting
  • Providence Medical Foundation - Fullerton - Virginia K. Crosson Cancer Center
    Fullerton, California 92835, United States
    Recruiting
  • University of California - Irvine
    Orange, California 92868, United States
    Recruiting
  • Vail Health Hospital - Shaw Cancer Center
    Edwards, Colorado 81632, United States
    Recruiting
  • Emory Winship Cancer Institute
    Atlanta, Georgia 30322, United States
    Recruiting
  • OSF Health Care
    Peoria, Illinois 61637, United States
    Recruiting
  • University of Michigan Health Systems
    Ann Arbor, Michigan 48109, United States
    Recruiting
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
    Recruiting
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
    Withdrawn

    Not enrolling at this site.

  • UT Southwestern Medical Center at Dallas
    Dallas, Texas 75390, United States
    Recruiting
  • Virginia Cancer Specialists PC
    Fairfax, Virginia 22031, United States
    Recruiting
  • Site FR33008
    Saint-Herblain, France
    Recruiting
  • Site FR33005
    Toulouse, France
    Recruiting
  • Site FR33001
    Villejuif, France
    Recruiting
  • Site ES34017
    Barcelona, Spain
    Recruiting
  • Site ES34006
    Madrid, Spain
    Recruiting
  • Site ES34011
    Madrid, Spain
    Recruiting
  • Site ES34008
    Málaga, Spain
    Recruiting
08

References and documents

Publications

  • Ou SI, Park CJ, Arter ZL, Nagasaka M. Successful and On-going Long-Term Disease Control (>24 Months) with Gilteritinib in an ALK+ NSCLC Patient with Brain Metastasis Who Has Progressed on Multiple ALK TKIs. A Case Report and Review of Literature on Gilteritnib. Lung Cancer (Auckl). 2025 Oct 22;16:139-145. doi: 10.2147/LCTT.S547128. eCollection 2025. PubMed 41158152 ↗

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Dec 2029, 51 months after the start.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 51 months is close to that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2025
First posted
Aug 24, 2025
StartActual
Sep 22, 2025
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2029
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
Hackensack University Medical Center is now Withdrawn
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Hackensack University Medical Center is now Withdrawn
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07140016
Responsible party
Sponsor
First posted
Aug 24, 2025
Start date
Sep 22, 2025
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Oct 23, 2026

Study contacts

Astellas Pharma Global Development, Inc.
Contact
Astellas.registration@astellas.com
800-888-7704
Medical Monitor
study director · Astellas Pharma Global Development, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gilteritinib

Start the discussion